^
No biomarker
NHL
C-CAR039
Sensitive: B - Late Trials
PRNewswire - 1 week
CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: C2 – Inclusion Criteria
Blood Adv - 3 weeks
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
No biomarker
NHL
brentuximab vedotin
Sensitive: A1 - Approval
ALK positive
NHL
crizotinib
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Burkitt Lymphoma
cyclophosphamide
Sensitive: A1 - Approval
No biomarker
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
ICP-022
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
ICP-022
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
CD20 expression
NHL
rituximab-arrx
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
No biomarker
NHL
carmustine
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
obinutuzumab
Sensitive: A1 - Approval
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
temsirolimus
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab + polatuzumab vedotin
Sensitive: A1 - Approval
No biomarker
NHL
pixantrone
Sensitive: A1 - Approval
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ibrutinib
Sensitive: A1 - Approval
No biomarker
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
ibrutinib
Sensitive: A1 - Approval
No biomarker
T Cell Non-Hodgkin Lymphoma
nelarabine
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
rituximab
Sensitive: A1 - Approval
TNFRSF8 positive
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
ibritumomab tiuxetan
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
bexarotene oral
Sensitive: A1 - Approval
TNFRSF8 expression
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
idelalisib
Sensitive: A1 - Approval
CD20 positive
NHL
rituximab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide + tafasitamab
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
duvelisib
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
belinostat
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
pralatrexate
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
selinexor
Sensitive: A1 - Approval
EZH2 wild-type
Follicular Lymphoma
tazemetostat
Sensitive: A1 - Approval
EZH2 mutation
Follicular Lymphoma
tazemetostat
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
copanlisib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
rituximab + ibrutinib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
umbralisib
Sensitive: A1 - Approval
No biomarker
Marginal Zone Lymphoma
umbralisib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
rituximab + bortezomib
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
vorinostat
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
acalabrutinib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
bortezomib
Sensitive: A1 - Approval
No biomarker
Marginal Zone Lymphoma
ibrutinib
Sensitive: A1 - Approval
IL2RA expression
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
CD20 positive
Follicular Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
No biomarker
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
CD20 positive
NHL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
rituximab/hyaluronidase
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab/hyaluronidase
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
avapritinib
Sensitive: A1 - Approval
No biomarker
NHL
recombinant Erwinia asparaginase
Sensitive: A1 - Approval
No biomarker
NHL
bendamustine
Sensitive: A1 - Approval
No biomarker
NHL
bendamustine RTD
Sensitive: A1 - Approval
CD20 positive
NHL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
Marginal Zone Lymphoma
R-CVP
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
R-CHOP
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
rituximab
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
CODOX-M + rituximab
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
R-CVAD
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
R-CVAD + cytarabine + methotrexate
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
EPOCH-R
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RGDP
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RICE
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RIVAC + methotrexate
Sensitive: A2 - Guideline